Pathogenic lipid‐binding antiphospholipid antibodies are associated with severity of COVID‐19
Anne Hollerbach, Nadine Müller‐Calleja, Denise Pedrosa, Antje Canisius, Martin F. Sprinzl, Tanja Falter, Heidi Rossmann, Marc Bodenstein, Christian Werner, Ingo Sagoschen, Thomas Münzel, Oliver Schreiner, Visvakanth Sivanathan, Michael Reuter, Johannes Niermann, Peter R. Galle, Luc Teyton, Wolfram Ruf, Karl J. Lackner
Topics & Concepts
MedicineCoagulopathyAntiphospholipid syndromeCoronavirus disease 2019 (COVID-19)AntibodyThrombosisCatastrophic antiphospholipid syndromeDiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Venous thrombosis2019-20 coronavirus outbreakImmunologyCoronavirusInternal medicineVirologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesSystemic Lupus Erythematosus ResearchHeparin-Induced Thrombocytopenia and Thrombosis